Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — H.C. Wainwright 25th Annual Global Investment Conference (September 2023)
22 slides from Inovio Pharmaceuticals's conference presentation, Sep 12, 2023
Slide 1: H.C. Wainwright Global Investment Conference
H.C. Wainwright Global Investment Conference September 12, 2023 :INO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,”” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding
Slide 3: Corporate Overview
Corporate Overview • Biotech company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases • Platform aims to optimize design & delivery to create therapies and vaccines that teach the body to manufacture it
Slide 4: 2023 Highlights
2023 Highlights • Prioritized our pipeline and right-sized the organization to focus on candidates with the greatest clinical promise, achievable pathways to market and strong commercial potential • Announced positive data from clinical trials for INO-3107 and INO-4201 − INO-3107: potential treatmen
Slide 5: Value Creation: A 3-Step Process
Value Creation: A 3-Step Process Potential to unlock the promise of DNA Medicines Lead Program Diversified Clinical Pipeline NextGen DNA Medicines INO-3107 • Potential treatment for RRP • 8 additional clinical-stage • dMAbs: targeting infectious • Breakthrough Therapy candidates disease designation
Slide 6: INOVIO's DNA Medicines
INOVIO's DNA Medicines 6
Slide 7: DNA Medicines Platform
DNA Medicines Platform Protective killer T cells and antibodies produced by immune system 7
Slide 8: Key Features of our DNA Medicines Platform
Key Features of our DNA Medicines Platform Induces antigen/protein-specific immune No anti-vector response; response offering therapeutic and ability to readminister and boost prophylactic protection Ability to drive antibody and CD8+ T cell No frozen storage or responses against multiple indication
Slide 9: Focus on HPV-Related Diseases
Focus on HPV-Related Diseases 9
Slide 10: Human Papillomavirus (HPV): A Global Concern
Human Papillomavirus (HPV): A Global Concern • HPV is a group of viruses with approximately 200 types • Nearly everyone will become infected with some HPV type in their lifetime − The good news: ~90% of all infections clear naturally and don't result in disease − The bad news: persistent infection c
Slide 11: INOVIO's Development Experience Across HPV Spectrum
INOVIO’s Development Experience Across HPV Spectrum • Studies ranging from Phase 1 to Phase 3 • Involving patients with RRP, HSIL (cervical, anal & vulvar), head and neck cancers 12 trials, 900+ participants, 2000+ administrations in HPV-related diseases 11
Slide 12: Example of DNA Medicine in HPV-Related Disease
Example of DNA Medicine in HPV-Related Disease Data from Phase 1/2a trial in HPV+ HNSCC Treatment with INO-3112 resulted in infiltration of CD8+ immune Robust antigen-specific T cell responses cells into the head and neck tumors (measured by staining of observed in peripheral blood (as measured by c
Slide 13: Lead Candidate: INO-3107 for RRP
Lead Candidate INO-3107 for RRP 13
Slide 14: Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP) • Rare disease caused by HPV-6/11, impacting both children and adults • Symptoms result from benign tumors – papillomas – in throat and on voice box • Surgery is current standard of care • Annual U.S. Incidence: − ~14K active cases − ~1.8 per 100,000 new ca
Slide 15: INO-3107 - DNA Medicine Targeting RRP
INO-3107 - DNA Medicine Targeting RRP • DNA Medicine product candidate composed of plasmids encoding for E6 and E7 antigens from HPV-6, HPV-11, and human interleukin-12 • Potential benefits: - Reduced number of surgical interventions - Generation of T cells, clearance of underlying HPV infection and
Slide 16: INO-3107 Phase 1/2 Trial: Decrease in Number of Surgeries
INO-3107 Phase 1/2 Trial: Decrease in Number of Surgeries • Overall, 26 patients (81.3%) had a decrease in surgical interventions in the year after INO-3107 administration versus the prior year • Decrease in surgeries: counted from start of treatment regimen (Day 0) − Even surgeries done during dosi
Slide 17: INO-3107: Phase 1/2 Trial Results - Cellular Response
INO-3107: Phase 1/2 Trial Results - Cellular Response • Treatment induced activated CD4 and CD8 T cells against E6/E7 antigens • Cytotoxic CD8 T cells thought to be important for clearance of virally infected cells • T-cell responses observed at Week 52 indicating persistent cellular memory response
Slide 18: INO-3107: Phase 1/2 Trial Results
INO-3107: Phase 1/2 Trial Results Prior to INO-3107 One Year Following INO-3107 Trial Participant: required frequent surgeries in the prior year Trial Participant: required no surgeries after Day 0 18 Vocal cord images RRP is a highly individualized disease and results of treatment with INO-3107 may
Slide 19: INOVIO Pipeline & Clinical Trials
INOVIO Pipeline & Clinical Trials Advancing DNA Medicines for Patients 19
Slide 20: Pipeline Overview
Pipeline Overview PRECLINICAL PHASE 1 PHASE 2 PHASE 3 INO-5401 INO-3107 BRCA1/2 Mutation RRP. VGX-3100 Anal Dysplasia INO-3112 Head & Neck Cancer INO-5401 Glioblastoma OUT-LICENSED* PRECLINICAL PHASE 1 PHASE 2 PHASE 3. VGX-3100 Cervical Dysplasia (HSIL) HPV-RELATED DISEASES @i IMMUNO-ONCOLOGY @@§§)
Slide 21: Active Clinical Studies with INOVIO DNA Medicines
Active Clinical Studies with INOVIO DNA Medicines 21
Slide 22: INOVIO: Drivers for Success
INOVIO: Drivers for Success Diversified Pipeline Unique Technology Experienced Leadership Power of Partnerships Advancing candidates Growing body of Extensive experience History of with scientific and research and late- bringing products to collaboration in clinical promise, stage clinical data mark